Third Annual “A Day of Remembrance” a video event to honor and remember those we have lost with myositis....
Orphazyme's Arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis, an incurable rare progressively debilitating muscle-wasting disease...
An Update on the Clinical Studies Using Arimoclomol as a Potential Treatment for Sporadic Inclusion Body Myositis VideoMyositis Support, , Featured, Inclusion Body Myositis (IBM)
The ongoing Arimoclomol Clinical Trial for sIBM continues to generate a lot of questions from our community. As part...
Today, Corbus Pharmaceuticals announced that the European Commission has approved orphan designation for lenabasum in the treatment of dermatomyositis...
We would like to let you know about a clinical research study that is available for patients diagnosed with...
Choose your language
- Explore Myositis
- Financial Assistance Program
- #ItsMyTurn: Becoming a Plasma Donor Hero
- Myositis Clinical Trials
- Myositis Empower Walk
- Myositis Webinars
- The Grieving Project
- Upcoming Events
- Donate today!